Lipitor Lawyer: Statin Drugs Cause Muscle Damage in 98%
Doctors have been encouraged to prescribe the cholesterol-lowering drugs called statins quite liberally. Patients who suffer heart attacks often have elevated levels of cholesterol, so statins like Lipitor are prescribed to lower the cholesterol. There have been no conclusive studies to prove the full effectiveness of these drugs, however, and some doctors worry that reducing cholesterol simply takes away the warning signs of heart disease. The drug companies also claim that statin drugs have a Read More...
Statins Drugs To Lower Your Cholesterol
Compared to other types of drugs, statins help lower the low-density lipoprotein cholesterol levels faster and more efficient. How does it work? Well, it helps lower the LDL levels by inhibiting an enzyme, HMG-CoA reductase that controls the rate of cholesterol production in the liver.
These drugs work by increasing the liver’s ability to remove low-density lipoprotein (also known as LDL cholesterol or bad cholesterol) already in the blood and by slowing down the total production of cholesterol Read More...
Coenzyme Q10, Muscle Pain and Statins, Are They Related?
Millions of Americans are taking medicine to lower their blood levels of cholesterol. Every day you see news stories, magazine articles, and television advertising that speak of the dangers of high LDL (bad) cholesterol and the importance of getting these levels as low as possible. In fact, the world’s best selling medicine is the cholesterol lowering medication, Lipitor. Other drugs in the same class of “statins” designed to lower cholesterol include Zocor, Vytorin, Crestor, Pravachol, Lesc Read More...
FDA Rejects Proposed Chronic Kidney Disease Indication for Vytorin The FDA rejected a new indication for Merck's Vytorin and Zetia (ezetimibe plus simvastatin and ezetimibe alone) in chronic kidney disease patients. As a consolation prize, however, the agency approved a new label for Vytorin that will incorporate the results of SHARP (Study of Heart and Renal Protection), which found that Vytorin reduced the incidence of major vascular events in patients with ... Read More...
Press Release Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an updated label for VYTORIN® (ezetimibe/simvastatin ) that includes results from the S tudy of H eart a nd R enal P rotection (SHARP). In SHARP, VYTORIN 10/20 mg lowered LDL cholesterol in patients with moderate to severe chronic kidney disease (CKD ... Read More...